Transplantation Immunology.pdf - E-Lib FK UWKS

24 Callaghan and Bradley
74. Matas, A. J., Gillingham, K. J., Payne, W. D., and Najarian, J. S. (1994) The
impact of an acute rejection episode on long-term renal allograft survival (t1/2).
Transplantation 57, 857–859.
75. Simon, T., Opelz, G., Wiesel, M., Ott, R. C., and Susal, C. (2003) Serial peripheral
blood perforin and granzyme B gene expression measurements for prediction
of acute rejection in kidney graft recipients. Am. J. Transplant. 3, 1121–1127.
76. Vasconcellos, L. M., Schachter, A. D., Zheng, X. X., et al. (1998) Cytotoxic lymphocyte
gene expression in peripheral blood leukocytes correlates with rejecting
renal allografts. Transplantation 66, 562–566.
77. Lederer, S. R., Friedrich, N., Regenbogen, C., Getto, R., Toepfer, M., and Sitter,
T. (2003) Non-invasive monitoring of renal transplant recipients: urinary excretion
of soluble adhesion molecules and of the complement-split product C4d.
Nephron Clin. Pract. 94, 19–26.
78. Magee, C. C., Denton, M. D., Womer, K. L., Khoury, S. J., and Sayegh, M. H.
(2004) Assessment by flow cytometry of intracellular cytokine production in the
peripheral blood cells of renal transplant recipients. Clin. Transplant. 18, 395–
401.
79. Hricik, D. E., Rodriguez, V., Riley, J., et al. (2003) Enzyme linked immunosorbent
spot (ELISPOT) assay for interferon-gamma independently predicts renal function
in kidney transplant recipients. Am. J. Transplant. 3, 878–884.
80. Gaber, A. O., First, M. R., Tesi, R. J., et al. (1998) Results of the double-blind,
randomized, multicenter, phase III clinical trial of thymoglobulin versus Atgam
in the treatment of acute graft rejection episodes after renal transplantation. Transplantation
66, 29–37.
81. Midtvedt, K., Fauchald, P., Lien, B., et al. (2003) Individualized T cell monitored
administration of ATG versus OKT3 in steroid-resistant kidney graft rejection.
Clin. Transplant. 17, 69–74.
82. Casadei, D. H., del C Rial, M., Opelz, G., et al. (2001) A randomized and prospective
study comparing treatment with high-dose intravenous immunoglobulin with
monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection.
Transplantation 71, 53–58.
83. Vincenti, F., Kirkman, R., Light, S., et al. (1998) Interleukin-2-receptor blockade
with daclizumab to prevent acute rejection in renal transplantation. Daclizumab
Triple Therapy Study Group. N. Engl. J. Med. 338,161–165.
84. Nashan, B., Moore, R., Amlot, P., Schmidt, A. G., Abeywickrama, K., and
Soulillou, J. P. (1997) Randomised trial of basiliximab versus placebo for control
of acute cellular rejection in renal allograft recipients. CHIB 201 International
Study Group. Lancet 350, 1193–1198.
85. Chilcott, J. B., Holmes, M. W., Walters, S., Akehurst, R. L., and Nashan, B. (2002)
The economics of basiliximab (Simulect) in preventing acute rejection in renal
transplantation. Transplant. Int. 15, 486–493.
86. Lederer, S. R., Kluth-Pepper, B., Schneeberger, H., Albert, E., Land, W., and
Feucht, H. E. (2001) Impact of humoral alloreactivity early after transplantation
on the long-term survival of renal allografts. Kidney Int. 59, 334–341.